Theradiag SA develops, manufactures, and markets in-vitro diagnostic products. More Details
Fair value with moderate growth potential.
Share Price & News
How has Theradiag's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALTER is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ALTER's weekly volatility has decreased from 13% to 5% over the past year.
7 Day Return
FR Medical Equipment
1 Year Return
FR Medical Equipment
Return vs Industry: ALTER exceeded the French Medical Equipment industry which returned -10.9% over the past year.
Return vs Market: ALTER underperformed the French Market which returned 35.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Theradiag's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is Theradiag undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ALTER (€1.97) is trading below our estimate of fair value (€3.19)
Significantly Below Fair Value: ALTER is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ALTER is unprofitable, so we can't compare its PE Ratio to the European Medical Equipment industry average.
PE vs Market: ALTER is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALTER's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALTER is good value based on its PB Ratio (3.2x) compared to the FR Medical Equipment industry average (3.4x).
How is Theradiag forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALTER is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).
Earnings vs Market: ALTER is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALTER's is expected to become profitable in the next 3 years.
Revenue vs Market: ALTER's revenue (4.6% per year) is forecast to grow slower than the French market (6.3% per year).
High Growth Revenue: ALTER's revenue (4.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALTER's Return on Equity is forecast to be high in 3 years time
How has Theradiag performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALTER is currently unprofitable.
Growing Profit Margin: ALTER is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALTER is unprofitable, but has reduced losses over the past 5 years at a rate of 33.1% per year.
Accelerating Growth: Unable to compare ALTER's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALTER is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (59.7%).
Return on Equity
High ROE: ALTER has a negative Return on Equity (-4.4%), as it is currently unprofitable.
How is Theradiag's financial position?
Financial Position Analysis
Short Term Liabilities: ALTER's short term assets (€9.3M) exceed its short term liabilities (€4.0M).
Long Term Liabilities: ALTER's short term assets (€9.3M) exceed its long term liabilities (€3.0M).
Debt to Equity History and Analysis
Debt Level: ALTER's debt to equity ratio (39.7%) is considered satisfactory.
Reducing Debt: ALTER's debt to equity ratio has increased from 1.5% to 39.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if ALTER has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALTER has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Theradiag current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALTER's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALTER's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALTER's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALTER's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALTER's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Bertrand De Castelnau (60 yo)
Mr. Bertrand de Castelnau serves as Chief Executive Officer at Theradiag SA since January 21, 2019 and as its Director since February 04, 2019. He began his career as a Commercial Attaché in Islamabad, Pak...
Experienced Board: ALTER's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Theradiag SA's company bio, employee growth, exchange listings and data sources
- Name: Theradiag SA
- Ticker: ALTER
- Exchange: ENXTPA
- Founded: 1986
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €17.047m
- Shares outstanding: 8.68m
- Website: https://www.theradiag.com
Number of Employees
- Theradiag SA
- 14 rue Ambroise Croizat
- CS 90136 Croissy Beaubourg
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products. It offers autoimmunity reagents; IMMUNO-TROL, a multi-parametric quality control tool; various instruments for autoimmunity an...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/21 22:29|
|End of Day Share Price||2021/09/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.